{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:28:37Z","timestamp":1791300517750,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.nmd.2016.08.013","type":"journal-article","created":{"date-parts":[[2016,9,9]],"date-time":"2016-09-09T20:31:16Z","timestamp":1473453076000},"page":"734-740","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Treatment and outcomes in necrotising autoimmune myopathy: An Australian perspective"],"prefix":"10.1016","volume":"26","author":[{"given":"Catherine","family":"Ashton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reimar","family":"Junckerstorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Bundell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hollingsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merrilee","family":"Needham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.nmd.2016.08.013_bib0010","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s11926-015-0548-6","article-title":"Immune-mediated necrotizing myopathy: update on diagnosis and management","volume":"17","author":"Basharat","year":"2015","journal-title":"Curr Rheumatol Rep [Internet]"},{"issue":"6","key":"10.1016\/j.nmd.2016.08.013_bib0015","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1097\/BOR.0b013e32834b324b","article-title":"Necrotizing autoimmune myopathy","volume":"23","author":"Liang","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.nmd.2016.08.013_bib0020","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1212\/01.CON.0000440662.26427.bd","article-title":"Inflammatory myopathies","volume":"19","author":"Amato","year":"2013","journal-title":"Contin Lifelong Learn Neurol"},{"issue":"5","key":"10.1016\/j.nmd.2016.08.013_bib0025","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/WCO.0b013e328364e9d9","article-title":"Acquired necrotizing myopathies","volume":"26","author":"Allenbach","year":"2013","journal-title":"Curr Opin Neurol"},{"issue":"9","key":"10.1016\/j.nmd.2016.08.013_bib0030","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1001\/jamaneurol.2015.1207","article-title":"Clinical features and treatment outcomes of necrotizing autoimmune myopathy","volume":"72","author":"Kassardjian","year":"2015","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1016\/j.nmd.2016.08.013_bib0035","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.nmd.2016.08.013_bib0040","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.21486","article-title":"Immune-mediated necrotizing myopathy associated with statins","volume":"41","author":"Grable-Esposito","year":"2010","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.1016\/j.nmd.2016.08.013_bib0045","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/mus.23854","article-title":"Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies: anti-HMGCR-associated myopathy","volume":"48","author":"Mohassel","year":"2013","journal-title":"Muscle Nerve"},{"issue":"6","key":"10.1016\/j.nmd.2016.08.013_bib0050","first-page":"728","article-title":"Myopathy associated with antibodies to signal recognition particle: disease progression and neurological outcome","volume":"69","author":"Suzuki","year":"2012","journal-title":"Arch Neurol [Internet]"},{"issue":"7","key":"10.1016\/j.nmd.2016.08.013_bib0055","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1365-2990.2012.01302.x","article-title":"Review: immune-mediated necrotizing myopathies \u2013 a heterogeneous group of diseases with specific myopathological features: immune mediated necrotizing myopathies","volume":"38","author":"Stenzel","year":"2012","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"2","key":"10.1016\/j.nmd.2016.08.013_bib0060","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/mus.24642","article-title":"The composition of cellular infiltrates in anti-HMG-CoA reductase-associated myopathy: anti-HMGCR myopathy infiltrate","volume":"52","author":"Chung","year":"2015","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.nmd.2016.08.013_bib0065","doi-asserted-by":"crossref","first-page":"e96","DOI":"10.1212\/NXI.0000000000000096","article-title":"Clinical course and treatment of anti-HMGCR antibody-associated necrotizing autoimmune myopathy","volume":"2","author":"Ramanathan","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"10.1016\/j.nmd.2016.08.013_bib0070","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/mus.24541","article-title":"Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase in patients with immune-mediated myositis and necrotizing myopathy","volume":"52","author":"Limaye","year":"2015","journal-title":"Muscle Nerve"},{"issue":"7","key":"10.1016\/j.nmd.2016.08.013_bib0075","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1056\/NEJMra1515161","article-title":"Statin-associated autoimmune myopathy","volume":"374","author":"Mammen","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.nmd.2016.08.013_bib0080","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","article-title":"119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10\u201312 October 2003, Naarden, The Netherlands","volume":"14","author":"Hoogendijk","year":"2004","journal-title":"Neuromuscul Disord"},{"issue":"8","key":"10.1016\/j.nmd.2016.08.013_bib0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11926-014-0433-8","article-title":"Is statin-induced myositis part of the polymyositis disease spectrum?","volume":"16","author":"Albayda","year":"2014","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.nmd.2016.08.013_bib0090","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2016-313166","article-title":"Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy","author":"Watanabe","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"10.1016\/j.nmd.2016.08.013_bib0095","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/art.30344","article-title":"Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy","volume":"63","author":"Benveniste","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.nmd.2016.08.013_bib0100","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.27572","article-title":"A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy","volume":"62","author":"Christopher-Stine","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.nmd.2016.08.013_bib0105","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/acr.20662","article-title":"Rarity of anti\u20133-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects","volume":"64","author":"Mammen","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"17","key":"10.1016\/j.nmd.2016.08.013_bib0110","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMc1506163","article-title":"Intravenous immune globulin for statin-triggered autoimmune myopathy","volume":"373","author":"Mammen","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.nmd.2016.08.013_bib0115","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1002\/acr.20219","article-title":"Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series","volume":"62","author":"Valiyil","year":"2010","journal-title":"Arthritis Care Res"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896616302863?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896616302863?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:04:30Z","timestamp":1760774670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896616302863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S0960896616302863"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2016.08.013","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment and outcomes in necrotising autoimmune myopathy: An Australian perspective","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2016.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2016 Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}